EFPIA - NEWSLETTER

EFPIA Newsletter 26 October 2017

News

25 October 2017 25102017 Industry and research associations call for maintaining EU Institutional Public Private...

Institutional Public Private Partnership (IPPP): a high value added funding instrument

Blogs

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicine is a long, complex and risky process with no guarantees of success. Over the coming weeks, we look at a number of new medicines and the role that pharmaceutical incentives (or IP) have played in their development.

26 October 2017 26102017 Incentives, IP and smaller companies – the story of ProAxsis

The development pipeline of ProAxsis: continued innovation fostered by incentives

26 October 2017 26102017 Hunter syndrome - Mucopolysaccharidosis Type II – EU Incentives Behind OMPs

The impact of incentives under the EU OMP Regulation

Events

21 NOV 2017

19 July 2017 War on Cancer – a patient’s journey The HAC, London, UK

3rd annual conference organised by The Economist Events

Learn more →

27 NOV 2017

14 July 2017 1st European Alliance for Personalised Medicine Congress Belfast, Northern Ireland

Personalising Your Health: A Global Imperative!

Learn more →

We published

Working together with patient groups 11 October 2017 (Publications)

A publication from the Patient Think Tank to provide guidance for collaboration

Health Collaboration Guide 2017 26 October 2017 (Publications)

Showcasing best practice collaborations between patient organisations and industry, but also local authorities, governments,...

What we are reading

Researchers agree to improve neurology/Alzheimer’s drug development 25 October 2017 (AlphaGalileo)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶